Formulating Inhaled and Intranasal Peptides & Proteins
Explore our latest white paper examining how advanced formulation science, particle engineering, and device integration can overcome the structural fragility of macromolecules. Discover how ABINITIO builds the protective delivery architecture required to reliably translate complex peptides, proteins, and RNA therapeutics into successful clinical outcomes.
Preclinical tools for early phase formulation development
Read our article on how upper respiratory in vitro models can be used to strengthen IVIVC and improve confidence in nasal and inhaled drug development before clinical studies.
Developing oligonucleotide therapies for lung delivery
Read our article on how nebulised oligonucleotide formulations can be developed and evaluated to supporteffective pulmonary delivery for chronic respiratory disease.
Predictive in vitro models
Read our article showing how upper respiratory in vitro models can improve translational relevance and reducedevelopment risk ahead of clinical studies.
mRNA therapeutics
Read our article exploring innovative polymer-based strategies to enhance intranasal delivery of mRNAtherapeutics.
Meeting challenges in inhaled drug delivery
Read our article exploring how complex challenges in inhaled drug delivery can be managed across development, scale up, and clinical readiness.